Lepu Biopharma Co., Ltd. (2157.HK)
HKD 4.19
(-0.95%)
HKD 4.19
(-0.95%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 225.35 Million CNY | 1347.16% |
| 2022 | 15.57 Million CNY | 0.0% |
| 2021 | - CNY | 0.0% |
| 2020 | - CNY | 0.0% |
| 2019 | - CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 72.22 Million HKD | -5.03% |
| 2024 Q2 | 71.6 Million HKD | -0.15% |
| 2023 Q3 | 38.5 Million HKD | -77.83% |
| 2023 FY | 225.35 Million CNY | 1347.16% |
| 2023 Q4 | 77.56 Million HKD | 101.45% |
| 2023 Q2 | 173.66 Million HKD | 97.88% |
| 2023 Q1 | 87.75 Million HKD | 402.26% |
| 2022 FY | 15.57 Million CNY | 0.0% |
| 2022 Q2 | - HKD | 0.0% |
| 2022 Q4 | 17.47 Million HKD | 0.0% |
| 2021 FY | - CNY | 0.0% |
| 2021 Q2 | - HKD | 0.0% |
| 2020 FY | - CNY | 0.0% |
| 2019 FY | - CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 484.71 Million HKD | 53.509% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.32 Billion HKD | 95.766% |